CERS2 and neoplasm: We confirmed that LASS2 overexpression significantly decreased the motility and invasiveness of multiple tumour cell lines (BCPAP, MDA-MB-231, Hepa1-6, and HepG2) compared to those of control cells (Fig. 6A and B).